Lupus News Today Home | Lupus News Today
WEBParvovirus, mpox, and COVID-19: 3 reasons to heighten precautions. Summer news reports show that COVID-19 is surging again. The World Health Organization has declared the mpox outbreak a global health emergency. And human parvovirus B19, which can cause fifth disease, is spreading across the U.S. Scientists are finding that, in …
Lupkynis approved in Japan to treat lupus nephritis
WEB4 days ago · Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare approved the treatment’s use in combination with the immunosuppressant mycophenolate mofetil. Otsuka Pharmaceutical filed a new drug application with ...
FDA updates Lupkynis label to include long-term efficacy data
WEBMay 6, 2024 · The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Lupkynis (voclosporin), which is approved to treat a severe manifestation of lupus called lupus nephritis, to include data that shows it continues to safely preserve kidney function for up to three years. The data came from AURORA 2 …
Lupkinis plus MMF most effective as treatment for lupus nephritis
WEBby Andrea Lobo, PhD January 8, 2024. A combination of Lupkinis (viclosporin) with mycophenolate mofetil (MMF) was the most effective at managing lupus nephritis, according to a systematic review of clinical trial data. The treatment was also associated with the highest risk of infections and serious infections, indicating a lower safety profile ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
WEBJul 24, 2023 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
Lupus overview - Lupus News Today
WEBFeb 9, 2023 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
Long-term safety of Lupkynis for SLE confirmed in AURORA trial
WEBApr 10, 2023 · New top-line data show participants in the Lupkynis treatment arm of the now completed Phase 3 AURORA trial (NCT03021499) had similar kidney biopsy (histologic) findings as those in the active control arm receiving mycophenolate mofetil, an immunosuppressant sold under the brand name CellCept, and low-dose steroids alone.. These results contrast with the well-known kidney-related side effects ...
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
WEBby Alice Melão September 29, 2017. New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study.
1st patient enrolled in global Phase 2 trial of daxdilimab for...
WEBMay 18, 2023 · A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative lupus nephritis (LN) — a lupus complication marked by kidney damage — has enrolled its first patient.
2 New Meds Found to Change Lupus Nephritis Treatment: Report
WEBJan 23, 2023 · Still many patients on high-dose corticosteroids, report finds. The analysis included data from 962 people with the disease in the U.S., as well as insights from 138 rheumatologists — autoimmune disease specialists — and 104 nephrologists, or …